Healthcare / Medical DevicesNasdaqGS
$17.69
+0.08 (+0.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-36.4M · quality 73.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$671M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.4%
↓Gross Margin
87.9%
↑Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+50.9%
FCF CAGR
—
FCF margin
-46.7%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $89.1M · net income $-53.4M · FCF $-41.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $89.1M | $89.1M | $65.4M | $45.2M | $25.9M |
| Net Income | $-53.4M | $-53.4M | $-40.5M | $-29.5M | $-37.2M |
| EBITDA | $-50.2M | $-50.2M | $-37.3M | $-26.5M | $-35.1M |
| EPS | — | — | -3.39 | -1.26 | -1.59 |
| Gross Margin | 87.9% | 87.9% | 86.7% | 84.4% | 82.9% |
| Operating Margin | -65.6% | -65.6% | -60.7% | -66.4% | -139.0% |
| Net Margin | -60.0% | -60.0% | -61.8% | -65.1% | -143.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.11 | -0.13 | -0.21 |
| Current Ratio | 10.44 | 10.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-41.6M | $-41.6M | $-36.4M | $-30.1M | $-32.5M |
| Returns | |||||
| ROE | -34.4% | -34.4% | -21.2% | 26.2% | 43.0% |
| Valuation | |||||
| P/B | 4.27 | 4.27 | 1.52 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 36.1% | 36.1% | 44.7% | 74.5% | — |
| EPS Growth | — | — | -168.4% | 20.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.39 → n/d
Residual
+3.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.